Baxter International Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Baxter is a global healthcare products company; results include its Hillrom business, acquired in December 2021. Unless otherwise noted, amounts are in U.S. dollars.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Net sales | $3.746B | $3.098B | $7.453B | $6.044B |
| Gross margin | $1.453B; 38.8% | $1.233B; 39.8% | $2.801B; 37.6% | $2.378B; 39.3% |
| Operating income | $340M | $424M | $503M | $814M |
| Net income attributable to Baxter | $252M | $298M | $323M | $596M |
| Diluted EPS | $0.50 | $0.59 | $0.64 | $1.17 |
| Operating cash flow | — | $482M | $854M |
- Reported sales rose 21% in Q2 and 23% in the first half. Hillrom contributed 23 and 24 percentage points, respectively; foreign exchange reduced growth by 5 and 4 percentage points. At constant currency, sales grew 26% and 27%.
- Operating income fell about 20% in Q2 and 38% in the first half; Baxter-attributable net income declined about 15% and 46%. Reported gross margin contracted 1.0 and 1.7 percentage points, respectively.
- Special items reduced net income by $191M in Q2 and $591M in the first half, or $0.37 and $1.16 per diluted share. Items included Hillrom-related amortization and integration costs, restructuring, regulatory compliance costs and product-related charges.
- First-half operating cash flow was $482M, down $372M year over year. The filing attributes the decrease primarily to lower net income, higher inventories and higher annual incentive payouts. Capital expenditures were $311M; investing cash outflow was $491M and financing cash outflow was $1.017B.
- At June 30, cash and cash equivalents were $1.852B, total current assets $7.882B and current liabilities $3.916B. Short-term debt was $200M; long-term debt and finance lease obligations, including current maturities, were about $16.5B. Revolving credit facilities totaling $2.5B and €200M had no outstanding borrowings; the company reported covenant compliance.
- Inventory increased to $2.663B from $2.453B at year-end 2021. Total assets were $31.831B, compared with $33.521B at December 31, 2021.
Material changes and management commentary
- Hillrom expanded reported revenue and added Patient Support Systems, Front Line Care and Surgical Solutions. Corporate costs increased substantially, including acquisition-related amortization, integration costs and optimization charges.
- Excluding special items, gross margin still declined year over year, mainly due to raw-material inflation and higher supply-chain costs; favorable product mix partly offset the pressure. SG&A also rose, reflecting Hillrom and increased outbound freight costs.
- Product performance was mixed. Medication Delivery and Advanced Surgery grew at constant currency; Acute Therapies and BioPharma Solutions weakened in Q2. Baxter cited supply constraints, lower COVID-related demand, China lockdowns, and slower hospital installations and access.
- Management reported more than $1.2B in expected cumulative annual pretax savings from optimization actions; approximately 99% was expected by year-end 2022 and the remainder by year-end 2023. About $29M of additional pretax implementation costs were expected for initiatives then underway. Further initiatives could bring additional costs.
- No specific full-year sales or earnings guidance is stated in the supplied filing text. Baxter said it expects continued uncertainty and potential adverse effects from supply-chain challenges, inflation, the pandemic and related restrictions.
Risks, contingencies and unusual items
- Supply-chain shortages and production interruptions have constrained some sales and raised costs. The company also identified COVID-related volatility, inflation, transportation disruption, weather events and the war in Ukraine as risks.
- The FDA re-inspected Baxter’s Ahmedabad, India facility in May 2022 and issued a Form 483; classification was pending. The pre-existing Claris Warning Letter had not been lifted. Baxter said it was implementing corrective actions and using alternative manufacturing locations.
- Two field corrective actions involving certain infusion pumps resulted in $23M of first-half product-related charges. Baxter also cited component shortages and pending U.S. FDA clearance of its new infusion-pump platform.
- Legal matters include an HHS/DOJ subpoena concerning Hillrom compliance, antitrust litigation brought by Linet, and other product and legal claims. The filing says some exposures cannot be estimated; outcomes could affect results or cash flows, though management did not expect the proceedings to materially harm consolidated financial position.
- Baxter settled an SEC matter in February 2022 without admitting or denying the findings and paid an $18M civil penalty. A prior shareholder securities class action settlement was approved in 2021.
- Upon future substantial liquidation of its Argentina operations, Baxter expects to reclassify a currency translation loss exceeding $60M from accumulated other comprehensive loss to earnings as a noncash charge.
- In March 2022 Baxter paid $122M for specified Zosyn rights and expects additional product rights to transfer in 2023. Hillrom purchase accounting remained preliminary at June 30, 2022.
Important facts for investors to verify
- How much of sales growth and future performance reflects Hillrom versus organic growth, currency movements and changing product demand.
- Whether supply constraints, inflation and pump-component shortages ease, and whether the new infusion-pump platform receives U.S. regulatory clearance.
- Progress on Hillrom integration, expected cost savings, remaining implementation costs and the impact of acquisition amortization on reported earnings.
- Cash conversion, inventory levels, debt repayment capacity and interest expense following the Hillrom acquisition.
- Updates on the Ahmedabad FDA warning letter/Form 483, Hillrom-related investigations and litigation, and other unresolved contingencies.
- Any subsequent guidance or changes to the optimization savings timeline; the filing does not provide clear full-year financial guidance.